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To study the cardiac determinants of regression of left 
ventricular hypertrophy in hypertension, left ventricular 
mass, fractional shortening and end-systolic wall stress 
were measured echocardiographically in 36 patients with 
essential hypertension and left ventricular hypertrophy. 
The patients were classified into two groups. Group I 
consisted of 15 patients with subnormal end-systolic wall 
stress, and Group II consisted of 21 patients with normal 
end-systolic wall stress. There were no significant differ- 
ences between groups in systolic or diastolic blood pressure. 
After treatment for 4.4 -C 1.7 years, echocardiographic 
studies were repeated. There were no significant differences 
between groups in the duration of the follow-up period and 
the kinds of antihypertensive drugs. 
After treatment, blood pressure decreased significantly 
in both groups (p < 0.001 for both), with no significant 
difference between groups. Left ventricular mass increased 
significantly in Group I (from 331 f 7 to 363 f 24 g, mean 
+ SEM, p < O.OS), whereas it decreased significantly in 
Group II (from 318 f 16 to 268 + 17 g, p < 0.001). 
Myocardial contractility (the relation between end-systolic 
wall stress and fractional shortening) remained almost the 
same as before treatment. 
In conclusion, in patients with hypertensive ventricular 
hypertrophy with subnormal end-systolic wall stress (inap- 
propriate hypertrophy, probably induced by a neuro- 
humoral factor), a decrease in blood pressure with antihy- 
pertensive treatment does not lead to regression of left 
ventricular hypertrophy, but rather to an increase in left 
ventricular mass. In patients with normal end-systolic wall 
stress (appropriate hypertrophy, probably induced by high 
arterial pressure) antihypertensive treatment decreases left 
ventricular mass if it has the potency to cause regression of 
hypertrophy. 
(J Am Co11 Cardiol1990;15:665-71) 
Left ventricular hypertrophy in essential hypertension can 
be reversed by medical treatment. Centrally acting alpha- 
adrenergic blockers (l), angiotensin-converting enzyme in- 
hibitors (2,3) and calcium channel antagonists (4) induce an 
effective reduction in left ventricular mass, whereas the 
effect of vasodilators (5), diuretic drugs (6) and beta- 
adrenergic blockers (7,s) is not as apparent. However, 
cardiac determinants in the regression of left ventricular 
hypertrophy in essential hypertension with antihypertensive 
treatment have not been studied. 
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Chronic pressure overloading of the heart is believed to 
lead to wall thickening that is commensurate with an in- 
creased systolic pressure and tends to normalize myocardial 
wall stress (appropriate hypertrophy) (9,lO). In hypertrophic 
cardiomyopathy, however, there is inappropriate hypertro- 
phy (1 l), which is probably caused by factors other than 
mechanical overload. It has been suggested experimentally 
(12) that, in addition to high arterial pressure, neurohumoral 
influences could have an important role in a left ventricular 
hypertrophy in hypertension. Also, in patients with hyper- 
tensive left ventricular hypertrophy with subnormal end- 
systolic wall stress, it has been suggested (13) that the 
beta-adrenergic response is increased, whereas in those with 
hypertensive left ventricular hypertrophy with normal end- 
systolic wall stress, the beta-adrenergic response is normal 
or becomes reduced (13). In hypertensive patients with 
subnormal end-systolic wall stress and an increased beta- 
adrenergic response, left ventricular hypertrophy (inappro- 
priate hypertrophy) might have been induced by a neuro- 
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humoral factor, but in those with normal end-systolic wall with a 2.25 MHz transducer. A two-dimensional echocardio- 
stress, left ventricular hypertrophy (appropriate hypertro- gram was recorded on a video system (Victor Umatic CR 
phy) might have been induced by high arterial pressure. This 6060) and M-mode echocardiograms were photographed on 
classification of hypertensive hypertrophy, according to the light-sensitive paper (Kodak Linagraph 1985) at a paper 
contribution made by high arterial pressure and a neuro- speed of 50 mm/s using a Honeywell 1956 strip chart 
humoral factor, may be useful in identifying the pathophys- recorder. Echocardiograms were obtained during expiration. 
iology in hypertensive patients. These two factors might A 12 lead ECG was also recorded. The measurements of 
have an influence on the regression of left ventricular hyper- echocardiograms were made by two observers (who were 
trophy in essential hypertension with antihypertensive treat- unaware of the patient’s clinical state) from at least six 
ment. consecutive cardiac cycles. 
In the present study, we attempted to study the cardiac 
determinants in the regression of left ventricular hypertro- 
phy in essential hypertension by antihypertensive treatment 
by classifying the patients with the same level of hyperten- 
sion and cardiac hypertrophy by left ventricular end-systolic 
wall stress and by investigating the influence of decreasing 
blood pressure. 
The thickness of the interventricular septum and the left 
ventricular posterior wall was measured at the time of the R 
wave on the ECG (end-diastole), with the ultrasound beam 
directed just below the tip of the anterior mitral leaflet on the 
M-mode echocardiogram. The thickness of the interventric- 
ular septum and the left ventricular posterior wall was 
measured by the Penn convention (14), which excludes right 
and left septal endocardial echo thickness from interventric- 
ular septal thickness and excludes posterior wall endocardial 
echo thickness from posterior wall thickness. Left septal 
endocardial thickness and posterior wall endocardial thick- 
ness are thus included in left ventricular diameter by this 
method. Diameter and thickness were measured at end- 
diastole and end-systole (when the endocardial surface of the 
septum was closest to the posterior wall of the left ventricle). 
All measurements were taken with a centimeter scale super- 
imposed on the echocardiogram. 
Methods 
Study patients. We studied 36 hypertensive patients with 
left ventricular hypertrophy who had had hypertension for 
>5 years. Blood pressure was measured by a cuff sphygmo- 
manometer, using phases 1 and 5 of the Korotkov sounds. 
Arterial hypertension was defined as a persistent systolic 
arterial pressure >150 mm Hg or a diastolic pressure >95 
mm Hg before any antihypertensive treatment was initiated 
or 4 weeks after its discontinuation. Essential hypertension 
was diagnosed in all 36 patients, and all displayed echocar- 
diographic evidence of left ventricular hypertrophy: (inter- 
ventricular septal wall thickness 112 mm at end-diastole, 
left ventricular end-diastolic posterior wall thickness 2 12 
mm and left ventricular mass >2 SD above the normal 
mean). 
To restrict the study to patients with pure hypertrophy, 
we studied only those who had a left ventricular end- 
diastolic diameter ~55 mm (32 men and 4 women, aged 18 to 
78 years). None of these patients had evidence of any other 
heart disease, as assessed by their cardiovascular history, 
physical examination, electrocardiogram (ECG) or echocar- 
diogram, and all had sinus rhythm without signs of heart 
failure. Because coronary arteriography was not justified in 
these patients, concomitant coronary artery disease had to 
be excluded on clinical grounds alone. Thus, the patients in 
this study had arterial hypertension without any clinically 
evident coronary artery disease. 
The patients gave informed consent to the tests, and the 
institutional committee on human research approved the 
study protocol. The tests were performed before the start of 
antihypertensive treatment or 4 weeks after its discontinua- 
tion. 
Estimation of left ventricular structure and function. M- 
mode and two-dimensional echocardiograms were obtained 
with a Toshiba SSH-11A cross-sectional ultrasonoscope 
Fractional shortening (an index of the ejection phase) 
was calculated as left ventricular end-diastolic diameter 
minus left ventricular end-systolic diameter divided by end- 
diastolic diameter. The result was expressed as a percent. 
Left ventricular mass was calculated by a pathologically 
validated regression method (14): 1.04 [(left ventricular 
end-diastolic diameter plus interventricular septal and pos- 
terior wall thicknesses)3 minus (left ventricular end-diastolic 
diameter3)] minus 14. 
End-systolic wall stress was calculated by the equation 
(15): (peak arterial pressure) times (left ventricular end- 
systolic diameter)2 divided by 4 (left ventricular wall thick- 
ness) times (left ventricular end-systolic diameter plus wall 
thickness). This is an expression of the average meridional 
wall stress, which may be defined as the force per unit area 
acting at the equatorial plane of the ventricle in the direction 
of the apex to base axis. Calculation of end-systolic wall 
stress from these measures has been validated (16,17). The 
blood pressure measurement used for calculation of end- 
systolic wall stress was taken at the time of the echocardio- 
graphic examination. In the group as a whole, there was no 
difference between blood pressure values taken at this time 
(156 ? 10 mm Hg) and the averages taken from the readings 
at the two different clinic visits before and just after the 
echocardiographic examination (156 2 13 mm Hg). Normal 
hemodynamic values obtained from healthy subjects were 
the same as noted in a previous study (13). 
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Table 1. Follow-Up Period and Administered Antihypertensive Drugs in Groups I and II 
Group 
I 
I1 
No. of 
Patients 
15 
21 
Follow-Up 
Period 
(yr) 
3.9 + 1.6 
4.9 ? 1.9 
Antihypertensive Drugs 
Calcium Channel 
Antagonist Beta-Blocker Diuretic Other 
9 (60%) 5 (33%) 6 (40%) 0 (0%) 
9 (43%) 6 (28%) 9 (43%) 4 (19%) 
Data are reported as mean values + I SD. 
The 36 patients were separated into two groups: Group I 
consisted of 15 patients with an end-systolic wall stress <2 
SD below the normal mean (~36.4 g/cm*), and Group II 
consisted of 21 patients with an end-systolic wall stress 
within 2 SD of the normal mean, (No patient in this study 
had an end-systolic wall stress >2 SD above the normal 
mean.) 
Antihypertensive treatment. More than 4 weeks before 
the study, five patients (33%) in Group I and seven patients 
(33%) in Group II were treated with antihypertensive agents. 
The duration of treatment was 4.8 ? 1.5 years in Group I and 
4.1 f 2.8 years in Group II. In Group I, four patients (44%) 
had taken a beta-adrenergic blocker, three (33%) a diuretic 
drug, 1 (11%) a calcium channel antagonist and one (11%) 
methyldopa. In Group II, three (33%), four (44%), one (11%) 
and one (11%) had taken the same drugs, respectively. Thus, 
there were no significant differences in treatment before the 
tests between the groups. 
Follow-up studies. After a baseline echocardiographic 
study was obtained, antihypertensive treatment was initi- 
ated. The kinds of antihypertensive drugs differed because 
their administration was determined by the physicians at the 
outpatient clinic. After a follow-up period of 4.5 2 1.7 years, 
the echocardiographic and ECG studies were repeated. 
The follow-up period and administered drugs in both 
groups are shown in Table 1. There were no significant 
differences between the groups. The estimation of patient 
compliance with antihypertensive treatment was assessed 
from pill counts at outpatient clinics. It proved that taking 
medication was reliable in all 36 patients. 
Statistical analysis. The t test, paired t test, correlation, 
regression equation and F test were used. All results with a 
value p < 0.05 were regarded as statistically significant. 
Results \ 
Baseline echocardiographic and hemodynamic characteris- 
tics. Baseline hemodynamic, echocardiographic and other 
variables are shown in Tables 2 and 3. There were no 
significant differences between the two groups in age, gender 
and systolic and diastolic blood pressure or left ventricular 
end-diastolic diameter (Table 3). Left ventricular end- 
systolic diameter was significantly smaller and fractional 
shortening was significantly greater in Group I than in Group 
II (p < O.Ol), probably as a result of the difference in 
end-systolic wall stress. There was no significant difference 
between groups in interventricular septal thickness (mean 16 
mm in Group I and 14 mm in Group II) Left ventricular 
posterior wall thickness was significantly larger in Group 1 
than in Group II (p < 0.005). There was asymmetric septal 
hypertrophy (interventricular septal thickness/left ventricu- 
lar posterior wall thickness ~1.3) in five patients (33%) in 
Group I and three patients (14%) in Group II (p = NS). 
Hypertrophy was noted in the apical region of the left 
ventricle in four patients in Group 1 and one in Group II. No 
patient had systolic anterior motion of the mitral valve. 
There was no significant difference between groups in left 
ventricular mass. End-systolic wall thickness (the average of 
the interventricular septal wall thickness and left ventricular 
posterior wall thickness at end-systole) was 22 t 3 mm in 
Group I and 20 5 2 mm in Group II (p = NS). 
Figure 1 shows the relation between end-systolic wall 
stress and fractional shortening in all 36 patients. There was 
a statistically significant inverse linear relation between 
end-systolic wall stress and fractional shortening (R = 
-0.894, p < 0.001). This indicates that the 15 patients in 
Group I and the 21 patients in Group II all had the same level 
of myocardial contractility. 
Follow-up data (Tables 2 and 3). Systolic blood pressure 
decreased significantly in both groups (p < O.OOl), and there 
was no significant difference between groups in the change in 
systolic blood pressure (Table 2). In both groups there were 
no significant changes in left ventricular end-diastolic diam- 
Table 2. Blood Pressure Before and After Treatment in 
Groups I and II 
Age SBP CSBP DBP 
(yr) M/F (mm Hg) (mm Hg) (mm Hg) 
Group I 
Before 55 ? 9 1411 151 ? I3 (6) 98 t 9 (4) 
After 133 2 9 (4) -19 + I4 86 + 7 (3) 
p value <o.oot <O.GQl 
Group II 
Before 51 * 11 1813 158 ? 9 (2) 96 t 12 (3) 
After 137 t I2 (2) -21 2 I3 83 ? 11 (2) 
p value <O.ool <O.ool 
Values are reported as mean values + I SD. with SEM values in 
parentheses. DBP = diastolic blood pressure: F = female; M = male; SBP = 
systolic blood pressure; LJSBP = change in systolic blood pressure with 
treatment. 
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Table 3. Echocardiographic Findings Before and After Treatment in Groups I and II 
Dd FS IVST PWT LV Mass ESS 
(mm) DS (%) (mm) (mm) (8) C&n*) 
Group I 
Before 
After 
p value 
Group II 
Before 
After 
p value 
43 2 4 (1) 21 23 51 ? 5 (1) 16 f 3 (1) 15 ? 2 (1) 331 ? 66 (7) 25.3 + 7.9 (1.8) 
45 ? 4 (I) 24 f 5 47 i 9 (2) 17 ? 3 (1) 14 * 3 (1) 363 ? 94 (24) 27.0 + 11.9 (2.7) 
NS NS NS NS NS co.05 NS 
48 of. 3 (1) 30 + 4 (1) 38 t 6 (I) 14 2 3 (1) 13 2 2 (0) 318 + 73 (16) 54.5 ? 16.0 (3.5) 
48 ? 3 (1) 30 + 3 (1) 38 + 6 (1) 13 * 3 (1) 11 * 2 (0) 268 + 79 (17) 50.1 + 1.2 (2.4) 
NS NS NS <O.ool <O.OOl <O.OOl NS 
Values are reported as mean values t 1 SD, with SEM in parentheses. Dd = left ventricular end-diastolic diameter; DS = left ventricular end-systolic 
diameter; ESS = left ventricular end-systolic wall stress; FS = fractional shortening; IVST = interventricular septal thickness; LV = left ventricular; PWT = 
left ventricular posterior wall thickness. 
eter (Table 3). Fractional shortening did not change signifi- 
cantly. Interventricular septal thickness and posterior wall 
thickness did not change in Group I, whereas both variables 
decreased significantly in Group II. (These changes were 
close to the limits of variability due to measurement error 
WW. 
Changes in the left ventricular mass (Table 3, Fig. 2). 
Left ventricular mass increased significantly (p < 0.05) in 
Group I, although some patients in the group had no change; 
in contrast, it decreased significantly (p < 0.001) in Group II. 
The changes in left ventricular mass differed among individ- 
uals in both groups. One reason may be that the various 
antihypertensive drugs taken by the patients (calcium chan- 
nel antagonists, beta-adrenergic blockers, diuretic drugs, for 
example) differed in ability to induce regression of cardiac 
hypertrophy. 
In this study, we separated the patients into two groups, 
but the data of Figure 1 suggest a continuum of end-systolic 
Figure 1. Relation between left ventricular end-systolic wall stress 
(ESS) and fractional shortening (FS) in all 36 patients before 
treatment. There was a significantly inverse linear relation. Broken 
lines show the regression line and 95% confidence interval. 
FS 
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wall stress values rather than two separate study cohorts. 
Figure 3 reveals the relation between end-systolic wall stress 
before treatment and the changes in left ventricular mass 
after treatment. There was a similar continuum in the 
regression of left ventricular mass by treatment. The patient 
data near the zero line for changes in left ventricular mass 
were at the border of the two groups. There were several 
exceptional patients; one of the reasons might be the dif- 
ferent kinds of antihypertensive drugs used, as just de- 
scribed. 
Group I subgroups. Because the standard deviation of 
repeat measurements of the left ventricular mass by M-mode 
Figure 2. The changes of the left ventricular (LV) mass with 
antihypertensive treatment in Groups I and II. A and B = after and 
before treatment, respectively. 
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Figure 3. Relation between left ventricular end-systolic wall stress 
(ESS) before treatment and changes (a) in left ventricular (LV) 
mass after treatment in all 36 patients. 0 = Group I; 0 = Group II. 
echocardiography is ~30 g in normal subjects with uncom- 
plicated essential hypertension (19) the 15 patients in Group 
I were separated into two subgroups: 5 patients with changes 
in left ventricular mass of 230 g (subgroup A) and 10 patients 
with changes ~30 g (subgroup B) (Table 4). The interven- 
tricular septal thickness was significantly larger in subgroup 
A than in subgroup B (p < 0.01). Other variables and 
treatments were not significantly different between sub- 
groups. 
Table 4. Comparison Between Group I Subgroups Defined by the 
Increase in Left Ventricular Mass After Treatment 
Increase in Left 
Ventricular Mass 
No. of patients at baseline study 
Age (yrl 
Male/female 
LV mass (g) 
IVS thickness (mm) 
Posterior wall thickness (mm) 
After treatment 
Follow-up period tyr) 
Calcium channel antagonist 
Beta-adrenergic blocker 
Diuretic 
Other 
230 g <30 g 
5 IO 
52 ? 5 57 ? 11 
5/O 910 
369 ? 12 317 ? 55 
19 ? 2 15 + 2 
I5 2 3 15 ? 2 
4.4 2 I.4 3.9 ? I.7 
3 (60%) 6 (60%) 
I (60%) 4 (40%) 
2 (40%) 4 (40%) 
0 (0%) 0 (0%) 
p Value 
NS 
NS 
NS 
co.01 
NS 
NS 
NS 
NS 
NS 
NS 
Values are expressed as mean values ? 1 SD. IVS = interventricular 
septum: LV = left ventricular. 
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Figure 4. Changes in myocardial contractility (relation between left 
ventricular end-systolic wall stress [ESS] and fractional shortening 
[FS]) with antihypertensive treatment. Regression lines with a 95% 
confidence interval obtained before the treatment (Fig. 1) are shown 
by the broken lines for Groups I and II. 
R wuve amplitude on the ECG decreased in Group II, but 
not in Group I. 
Changes in myocardial contractility (Fig. 4). The relation 
between left ventricular end-systolic wall stress and frac- 
tional shortening axis shown in Figure 4, with the regression 
lines obtained before treatment. In both groups, end-systolic 
wall stress, fractional shortening and myocardial contractil- 
ity did not change significantly (Table 3). 
Discussion 
Methodologic considerations. Reproducibility of echocar- 
diographic results is tenuous if rigid techniques for the 
consistency of measurements are not utilized. These tech- 
niques include angulation of the ultrasound beam, location of 
measurement. double-blind reading and strict application of 
reading criteria. Averaging the results of two observers, 
using the same technicians and assessing the M-mode rec- 
ords from the two-dimensional long-axis view may optimize 
the reproducibility of serial results (20). 
Echocardiographic studies of the regression of the left 
ventricular hypertrophy in hypertension have been reported 
(21-23). Because the standard deviation of repeated mea- 
surements of left ventricular mass by M-mode echocardiog- 
raphy has been shown to be ~30 g in normal subjects or 
those with uncomplicated essential hypertension (19), the 
increase in left ventricular mass in Group I and its decrease 
in Group II in the present study may be significant, not only 
statistically but also methodologically. 
Regression of left ventricular hypertrophy in hypertension. 
In general, the reduction in left ventricular mass becomes 
evident after at least 8 to 12 weeks of antihypertensive 
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therapy (1,24), but the ability to induce this regression varies 
markedly among otherwise equipotent antihypertensive 
agents. Centrally acting alpha-adrenergic blockers (l), an- 
giotensin-converting enzyme inhibitors (2,3) and calcium 
channel antagonists (4) induce an effective reduction in left 
ventricular mass, whereas the effect of vasodilators (5), 
diuretic drugs (6) and beta-adrenergic blockers (7,8) is less 
apparent. 
The mechanism of the difierent efects of the drugs on left 
ventricular hypertrophy is not clear, but it is possible that the 
different pharmacologic effects of the drugs on hemody- 
namic, neural and humoral factors may contribute to this 
discrepancy. 
Determinants of hypertensive hypertrophy. In this study, 
the patients were separated into two groups according to 
their end-systolic wall stress. End-systolic wall stress relates 
to systolic blood pressure, left ventricular end-systolic di- 
ameter and end-systolic wall thickness. Systolic blood pres- 
sure was not significantly different between the two groups, 
and myocardial contractility was the same in both groups. In 
Group I, end-systolic wall stress was smaller than in Group 
II, and fractional shortening was larger with a smaller 
end-systolic diameter. End-systolic wall thickness was not 
significantly different between groups. Thus, the difference 
in end-systolic wall stress between the two groups cannot be 
explained by pressure overloading or myocardial contractil- 
ity. Either a lack of correlation or a relatively poor correla- 
tion between the degree of blood pressure control and 
regression of left ventricular hypertrophy was demonstrated 
(1,24). The correlation between left ventricular mass and 
blood pressure was reported (25) to improve when investi- 
gators used the average of 24 h blood pressure recordings 
rather than casual blood pressure levels, but even then the 
index of correlation reached only 36% at best. It is known (1) 
that a reversal of left ventricular hypertrophy does not occur 
equally in all individuals treated with the same medication. 
It has been suggested (11) that, in addition to high arterial 
pressure, neurohumoral influences could play an important 
role in cardiac hypertrophy in hypertension. Small doses of 
isoproterenol or other catecholamines produced hypertro- 
phy in laboratory animals without changing the blood pres- 
sure or heart rate (26,27). Most studies of cardioadrenergic 
support in left ventricular hypertrophy have dealt with the 
better known beta-adrenergic system. This cardioadrenergic 
support has also been studied through the alpha-adrenergic 
receptor in cultured neonatal rat heart cells (28). 
As mentioned, the problem of regression in left ventric- 
ular hypertrophy in essential hypertension has been ap- 
proached from the pharmacologic aspect, but has not been 
approached from the viewpoint of the cardiac condition. Our 
present study has shown that regression of left ventricular 
hypertrophy is dependent not only on the kinds of antihy- 
pertensive drugs, but also on the hemodynamic status of the 
heart (that is, the mechanism of development of left ventric- 
ular hypertrophy) , 
In hypertensive patients with normal left ventricular 
end-systolic wall stress, left ventricular hypertrophy (appro- 
priate hypertrophy) might have been induced by high arterial 
pressure, and the hypertrophy might have regressed as a 
result of decreasing the mechanical load with an antihyper- 
tensive drug had the drug been potent enough to cause 
regression of left ventricular hypertrophy. On the other 
hand, in those with subnormal end-systolic wall stress, left 
ventricular hypertrophy (inappropriate hypertrophy) might 
have been induced by a neurohumoral factor, and the 
hypertrophy could not regress as a result of a decrease in 
blood pressure caused by the antihypertensive drug, even if 
the drug had the potency to cause regression of left ventric- 
ular hypertrophy. 
As mentioned, one of the determinants in the regression 
of left ventricular hypertrophy with antihypertensive treat- 
ment may be a neurohumoral factor. It is known (13) that left 
ventricular hypertrophy with subnormal left ventricular end- 
systolic wall stress (inappropriate hypertrophy) is more 
responsive to beta-adrenergic stimulation than is hypertro- 
phy with normal end-systolic wall stress. This might be 
related to the increase in left ventricular mass after treatment 
in Group I in our present study. 
There was no difference between patients in Group I 
whose left ventricular mass increased and patients in Group 
II whose mass did not increase, except in interventricular 
septal thickness. This increased septal thickness might sup- 
port the similarity to hypertrophic cardiomyopathy. In more 
than half of the patients, calcium channel antagonists were 
administered. French et al. (29) showed that long-term 
infusion of verapamil produced biventricular and septal 
hypertrophy in conscious dogs, postulating that either an 
increase in catecholamines or a direct action of verapamil on 
the myocardium may be responsible for ventricular hyper- 
trophy. Their result may be coincident with the result in 
Group I in our study. It has been reported (13) that in 
patients with hypertensive hypertrophy with subnormal end- 
systolic wall stress (as in patients in our Group I), the 
beta-adrenergic response increased. This might support the 
postulate of French et al. (29). 
It has been reported (30,31) that progression of left 
ventricular hypertrophy is absent or present in some adult 
patients with hypertrophic cardiomyopathy. It has also been 
reported (32-34) that interventricular septal thickness was 
reduced or showed no change after long-term administration 
of verapamil in patients with hypertrophic cardiomyopathy, 
but some of the patients in these reports showed an increase 
in septal thickness with the administration of verapamil. 
Thus, in some patients with hypertensive hypertrophy (our 
Group I) or hypertrophic cardiomyopathy, calcium channel 
antagonists might induce progression of hypertrophy. 
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Clinical implications. Left ventricular hypertrophy in es- 
sential hypertension can be reversed by medical treatment, 
and the reduction varies according to the kinds of antihyper- 
tensive drugs used. The present study suggests that the 
cardiac (hemodynamic) factor is also an important determi- 
nant in regression of left ventricular hypertrophy. Chronic 
pressure overloading of the heart is believed to lead to wall 
thickening that is commensurate with an increased systolic 
pressure and tends to normalize myocardial wall stress 
(appropriate hypertrophy) (9,lO). Therefore, in hypertensive 
patients with hypertrophy and normal end-systolic wall 
stress, left ventricular hypertrophy might be induced by the 
high arterial pressure, and left ventricular hypertrophy might 
regress with an antihypertensive drug if the drug has the 
potency to induce regression of the hypertrophy. In con- 
trast, in patients with subnormal end-systolic wall stress, left 
ventricular hypertrophy (inappropriate hypertrophy) might 
be induced by a neurohumoral factor, and left ventricular 
hypertrophy cannot regress as a result of a decrease in blood 
pressure induced by an antihypertensive drug, even if the 
drug has the ability to cause regression of hypertrophy. 
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